ICON Public Limited Company (ICLR)
USD 143.12
(4.63%)
USD 143.12
(4.63%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 956.15 Million USD | 33.12% |
| 2022 | 795.23 Million USD | 30.69% |
| 2021 | 608.47 Million USD | 55.24% |
| 2020 | 391.96 Million USD | -9.56% |
| 2019 | 433.4 Million USD | 14.93% |
| 2018 | 377.11 Million USD | 13.61% |
| 2017 | 331.94 Million USD | 6.5% |
| 2016 | 311.69 Million USD | 10.71% |
| 2015 | 281.53 Million USD | 39.13% |
| 2014 | 202.35 Million USD | 67.0% |
| 2013 | 121.16 Million USD | 74.17% |
| 2012 | 69.56 Million USD | 136.28% |
| 2011 | 29.44 Million USD | -68.03% |
| 2010 | 92.09 Million USD | -14.29% |
| 2009 | 107.45 Million USD | 7.99% |
| 2008 | 99.5 Million USD | 43.7% |
| 2007 | 69.24 Million USD | 44.81% |
| 2006 | 47.81 Million USD | 0.0% |
| 2005 | - USD | -100.0% |
| 2004 | 34.38 Million USD | 37.92% |
| 2003 | 24.92 Million USD | 36.87% |
| 2002 | 18.21 Million USD | 64.44% |
| 2001 | 11.07 Million USD | 35.94% |
| 2000 | 8.14 Million USD | 25.35% |
| 1999 | 6.5 Million USD | -84.56% |
| 1998 | 42.1 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | 285.43 Million USD | 1.05% |
| 2024 Q2 | 282.46 Million USD | -3.43% |
| 2024 Q1 | 292.48 Million USD | 6.27% |
| 2023 Q1 | 216.78 Million USD | 6.6% |
| 2023 FY | 1.05 Billion USD | 33.12% |
| 2023 Q4 | 275.22 Million USD | 4.13% |
| 2023 Q2 | 209.48 Million USD | -3.37% |
| 2023 Q3 | 264.31 Million USD | 26.17% |
| 2022 FY | 795.23 Million USD | 30.69% |
| 2022 Q1 | 170.33 Million USD | 17.85% |
| 2022 Q2 | 177.78 Million USD | 4.37% |
| 2022 Q3 | 243.74 Million USD | 37.1% |
| 2022 Q4 | 203.36 Million USD | -16.57% |
| 2021 FY | 608.47 Million USD | 55.24% |
| 2021 Q1 | 116.01 Million USD | -3.21% |
| 2021 Q4 | 144.53 Million USD | 2729.58% |
| 2021 Q3 | 5.1 Million USD | -95.47% |
| 2021 Q2 | 112.87 Million USD | -2.71% |
| 2020 Q4 | 119.85 Million USD | 10.57% |
| 2020 Q3 | 108.4 Million USD | 90.35% |
| 2020 FY | 391.96 Million USD | -9.56% |
| 2020 Q2 | 56.94 Million USD | -46.42% |
| 2020 Q1 | 106.29 Million USD | -7.83% |
| 2019 Q2 | 106.09 Million USD | 4.06% |
| 2019 Q1 | 101.94 Million USD | 0.16% |
| 2019 Q3 | 110.04 Million USD | 3.73% |
| 2019 FY | 433.4 Million USD | 14.93% |
| 2019 Q4 | 115.32 Million USD | 4.8% |
| 2018 Q2 | 81.91 Million USD | -10.69% |
| 2018 FY | 377.11 Million USD | 13.61% |
| 2018 Q3 | 97.94 Million USD | 19.57% |
| 2018 Q4 | 101.78 Million USD | 3.93% |
| 2018 Q1 | 91.72 Million USD | 2.2% |
| 2017 Q3 | 84.93 Million USD | 8.9% |
| 2017 Q2 | 77.99 Million USD | -8.94% |
| 2017 Q1 | 85.65 Million USD | 1.2% |
| 2017 FY | 331.94 Million USD | 6.5% |
| 2017 Q4 | 89.74 Million USD | 5.66% |
| 2016 Q4 | 84.64 Million USD | 9.76% |
| 2016 Q3 | 77.11 Million USD | 4.31% |
| 2016 Q1 | 76.01 Million USD | 0.88% |
| 2016 FY | 311.69 Million USD | 10.71% |
| 2016 Q2 | 73.92 Million USD | -2.74% |
| 2015 Q1 | 66.67 Million USD | 29.11% |
| 2015 Q3 | 71.38 Million USD | 4.78% |
| 2015 FY | 281.53 Million USD | 39.13% |
| 2015 Q4 | 75.34 Million USD | 5.55% |
| 2015 Q2 | 68.13 Million USD | 2.19% |
| 2014 Q1 | 42.99 Million USD | 11.07% |
| 2014 FY | 202.35 Million USD | 67.0% |
| 2014 Q4 | 51.64 Million USD | -13.1% |
| 2014 Q2 | 48.28 Million USD | 12.3% |
| 2014 Q3 | 59.42 Million USD | 23.06% |
| 2013 Q4 | 38.71 Million USD | 16.74% |
| 2013 Q3 | 33.16 Million USD | 26.09% |
| 2013 Q2 | 26.29 Million USD | 14.36% |
| 2013 FY | 121.16 Million USD | 74.17% |
| 2013 Q1 | 22.99 Million USD | -5.76% |
| 2012 Q1 | 11.73 Million USD | 76.42% |
| 2012 Q2 | 11 Million USD | -6.21% |
| 2012 Q3 | 20.87 Million USD | 89.74% |
| 2012 Q4 | 24.4 Million USD | 16.87% |
| 2012 FY | 69.56 Million USD | 136.28% |
| 2011 Q2 | 15.5 Million USD | 41.36% |
| 2011 Q4 | 6.65 Million USD | 280.61% |
| 2011 Q3 | -3.68 Million USD | -123.75% |
| 2011 FY | 29.44 Million USD | -68.03% |
| 2011 Q1 | 10.96 Million USD | -50.17% |
| 2010 Q3 | 17.62 Million USD | -31.36% |
| 2010 Q2 | 25.67 Million USD | -4.11% |
| 2010 Q1 | 26.77 Million USD | -9.99% |
| 2010 FY | 92.09 Million USD | -14.29% |
| 2010 Q4 | 22.01 Million USD | 24.9% |
| 2009 Q4 | 29.75 Million USD | -2.17% |
| 2009 Q1 | 26.91 Million USD | 1.7% |
| 2009 FY | 107.45 Million USD | 7.99% |
| 2009 Q3 | 30.4 Million USD | 3.72% |
| 2009 Q2 | 29.31 Million USD | 8.93% |
| 2008 Q1 | 21.51 Million USD | 106.49% |
| 2008 FY | 99.5 Million USD | 43.7% |
| 2008 Q4 | 26.46 Million USD | -2.45% |
| 2008 Q3 | 27.13 Million USD | 11.22% |
| 2008 Q2 | 24.39 Million USD | 13.4% |
| 2007 Q3 | 18.7 Million USD | 16.46% |
| 2007 FY | 69.24 Million USD | 44.81% |
| 2007 Q1 | 14.69 Million USD | 6.44% |
| 2007 Q4 | -331.35 Million USD | -1871.67% |
| 2007 Q2 | 16.06 Million USD | 9.31% |
| 2006 FY | 47.81 Million USD | 0.0% |
| 2006 Q3 | 12.61 Million USD | 11.25% |
| 2006 Q4 | 13.8 Million USD | 9.45% |
| 2006 Q1 | 10.06 Million USD | 11.62% |
| 2006 Q2 | 11.33 Million USD | 12.62% |
| 2005 Q4 | 9.01 Million USD | 7.77% |
| 2005 FY | - USD | -100.0% |
| 2005 Q1 | -5.23 Million USD | -174.73% |
| 2005 Q2 | 7.35 Million USD | 240.37% |
| 2005 Q3 | 8.36 Million USD | 13.83% |
| 2004 FY | 34.38 Million USD | 37.92% |
| 2004 Q2 | 9.63 Million USD | 10.06% |
| 2004 Q3 | 9.48 Million USD | -1.6% |
| 2004 Q4 | 7 Million USD | -26.11% |
| 2004 Q1 | 8.75 Million USD | 4.71% |
| 2003 Q1 | 6.18 Million USD | -1.7% |
| 2003 FY | 24.92 Million USD | 36.87% |
| 2003 Q4 | 8.36 Million USD | 9.73% |
| 2003 Q3 | 7.62 Million USD | 5.44% |
| 2003 Q2 | 7.22 Million USD | 16.86% |
| 2002 Q4 | 6.29 Million USD | 20.53% |
| 2002 FY | 18.21 Million USD | 64.44% |
| 2002 Q2 | 5.06 Million USD | 9.25% |
| 2002 Q1 | 4.63 Million USD | 5.29% |
| 2002 Q3 | 5.22 Million USD | 3.04% |
| 2001 Q3 | 4.1 Million USD | 1660.08% |
| 2001 Q1 | 4.07 Million USD | 57.42% |
| 2001 Q4 | 4.4 Million USD | 7.36% |
| 2001 Q2 | -263 Thousand USD | -106.46% |
| 2001 FY | 11.07 Million USD | 35.94% |
| 2000 Q3 | 2.33 Million USD | -1.6% |
| 2000 Q4 | 2.58 Million USD | 11.03% |
| 2000 Q2 | 2.36 Million USD | 3.68% |
| 2000 Q1 | 2.28 Million USD | 26.94% |
| 2000 FY | 8.14 Million USD | 25.35% |
| 1999 Q4 | 1.8 Million USD | 20.0% |
| 1999 FY | 6.5 Million USD | -84.56% |
| 1999 Q2 | -34.8 Million USD | -336.73% |
| 1999 Q1 | 14.7 Million USD | 7.3% |
| 1999 Q3 | 1.5 Million USD | 104.31% |
| 1998 Q4 | 13.7 Million USD | 7.03% |
| 1998 Q2 | 12.1 Million USD | 21.0% |
| 1998 Q1 | 10 Million USD | 0.0% |
| 1998 FY | 42.1 Million USD | 0.0% |
| 1998 Q3 | 12.8 Million USD | 5.79% |
| 1997 Q4 | 10 Million USD | 0.0% |
| 1997 Q3 | 10 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 1082.109% |
| Applied DNA Sciences, Inc. | -10.95 Million USD | 8829.359% |
| Aspira Women's Health Inc. | -18.85 Million USD | 5171.886% |
| Biodesix, Inc. | -41.34 Million USD | 2412.786% |
| BioNexus Gene Lab Corp. | -2.59 Million USD | 36965.994% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | 12092.031% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | 12092.031% |
| Bionano Genomics, Inc. | -215.24 Million USD | 544.216% |
| CareDx, Inc | -101.9 Million USD | 1038.324% |
| Check-Cap Ltd. | -19.28 Million USD | 5057.495% |
| Castle Biosciences, Inc. | -67.97 Million USD | 1506.582% |
| DarioHealth Corp. | -56.18 Million USD | 1801.671% |
| Exact Sciences Corporation | -215.01 Million USD | 544.697% |
| Fulgent Genetics, Inc. | -72.69 Million USD | 1415.293% |
| Guardant Health, Inc. | -564.72 Million USD | 269.313% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 12.85% |
| Illumina, Inc. | -1.06 Billion USD | 189.444% |
| Intelligent Bio Solutions Inc. | -10.28 Million USD | 9398.219% |
| iSpecimen Inc. | -11.16 Million USD | 8660.499% |
| Standard BioTools Inc. | -76.6 Million USD | 1348.24% |
| MDxHealth SA | -27.32 Million USD | 3598.928% |
| 23andMe Holding Co. | -321.35 Million USD | 397.537% |
| Medpace Holdings, Inc. | 336.82 Million USD | -183.872% |
| Myriad Genetics, Inc. | -123.7 Million USD | 872.96% |
| Mainz Biomed B.V. | -26.64 Million USD | 3688.528% |
| ENDRA Life Sciences Inc. | -10.52 Million USD | 9188.262% |
| NeoGenomics, Inc. | -107.73 Million USD | 987.495% |
| Neogen Corporation | 58.66 Million USD | -1529.906% |
| Inotiv, Inc. | -81.46 Million USD | 1273.769% |
| Natera, Inc. | -446.24 Million USD | 314.266% |
| OpGen, Inc. | -15.68 Million USD | 6194.613% |
| OPKO Health, Inc. | -157.02 Million USD | 708.933% |
| Psychemedics Corporation | -2.92 Million USD | 32833.721% |
| Prenetics Global Limited | -52.51 Million USD | 1920.772% |
| Prenetics Global Limited | -52.51 Million USD | 1920.772% |
| Precipio, Inc. | -7.62 Million USD | 12647.927% |
| Personalis, Inc. | -109.93 Million USD | 969.735% |
| RadNet, Inc. | 98.69 Million USD | -868.775% |
| Sera Prognostics, Inc. | -39.82 Million USD | 2501.125% |
| Sotera Health Company | 276.69 Million USD | -245.565% |
| Neuronetics, Inc. | -30.55 Million USD | 3229.384% |
| Star Equity Holdings, Inc. | -4.34 Million USD | 22100.736% |
| Star Equity Holdings, Inc. | -4.34 Million USD | 22100.736% |
| Trinity Biotech plc | -27.04 Million USD | 3635.411% |
| T2 Biosystems, Inc. | -49.66 Million USD | 2025.242% |
| Twist Bioscience Corporation | -220.83 Million USD | 532.979% |
| Exagen Inc. | -22.83 Million USD | 4286.855% |